

Special Issue

Role of Glycomics in Diagnosis and Prognosis of Cancers

Message from the Guest Editor

A multitude of -omic fields are being studied for their involvement in cancer. For a long time, glycoproteins have been of great interest in biomarker research as many changes in protein chemistry can be associated with actual changes in protein glycosylation. This variation seen in the glycome is the result of genetic and environmental factors, which also play a major role in the onset of many disease. Therefore, variations in glycosylation patterns have been linked to a multitude of pathological conditions, providing precious insight into the cellular functions underlying these pathological conditions. In this Special Issue, we aim to cover the most recent advances regarding glycomic research in cancer. The main focus will be on, but not limited to, the pathophysiological role of the glycome in cancer development and progression, use of glycans for disease diagnosis, risk stratification and prognosis through glycan variation, as well as innovative tools and methodological approaches to assess glycan-related biomarkers. In this Special Issue, we welcome any kind of papers on the aforementioned subject.

Guest Editor

Dr. Tijl Vermassen

Department Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium

Deadline for manuscript submissions

closed (30 September 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/164549

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).